Anti-Cancer Drugs最新文献_第10页

Surufatinib combined camrelizumab as a valuable third-line rescue therapy for a patient with extensive-stage for small-cell lung cancer: a case report and literature review. 苏法替尼联合卡雷珠单抗作为一种有价值的小细胞肺癌癌症晚期患者的第三线抢救疗法：病例报告和文献综述。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-11-21 DOI: 10.1097/CAD.0000000000001552

Chi Pan, Tao Yu, Li Han, Daxuan Hao, Ming Yang, Lin Li, Laili Chu, Qingtao Ni

引用次数: 0

miR-26b-5p suppresses chemoresistance in breast cancer by targeting serglycin: Erratum. miR-26b-5p 通过靶向丝胶蛋白抑制乳腺癌的化疗耐药性勘误。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI: 10.1097/CAD.0000000000001579

引用次数: 0

Suppression of DNMT1 combined with ATM or ATR inhibitor as a therapeutic combination of acute myeloid leukemia. 抑制 DNMT1 与 ATM 或 ATR 抑制剂联合治疗急性髓性白血病。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-12-27 DOI: 10.1097/CAD.0000000000001564

Lei Liu, Xiaoyan Hu, Jing Feng, Anhui Lei, Shiying Huang, Xian Liu, Hui Liu, Lan Luo, Wenyan Yao

{"title":"Suppression of DNMT1 combined with ATM or ATR inhibitor as a therapeutic combination of acute myeloid leukemia.","authors":"Lei Liu, Xiaoyan Hu, Jing Feng, Anhui Lei, Shiying Huang, Xian Liu, Hui Liu, Lan Luo, Wenyan Yao","doi":"10.1097/CAD.0000000000001564","DOIUrl":"10.1097/CAD.0000000000001564","url":null,"abstract":"The potential treatment option of targeting DNA methyltransferase 1 (DNMT1) has been explored, but further investigation is required to assess the efficacy of combination therapy in acute myeloid leukemia (AML). In this study, bioinformatics and online databases were utilized to select the combined therapeutic targets. The potential kinases associated with DNMT1-related genes in AML were analyzed using the Cancer Genome Atlas (TCGA) database and X2K Appyter (Expression2Kinases) database. In-vitro evaluations were conducted to assess the synergistic effects between DNMT1 and ATR/ATM in five AML cell lines (MOLM-16, NB-4, HEL 92.1.7, HEL, EOL-1). In our study, ATR and ATM are primarily the kinases associated with DNMT1-related genes in AML. We observed a significant upregulation of DNMT1, ATR, and ATM expression in AML tissues and cell lines. The five AML cell lines demonstrated sensitivity to monotherapy with GSK-368, AZD-1390, or AZD-6738 (EC50 value ranges from 5.461 to 7.349 nM, 5.821 to 10.120 nM, and 7.618 to 10.100 nM, respectively). A considerable synergistic effect was observed in AML cell lines when combining GSK-368 and AZD-1390, GSK-368 and AZD-6738, or AZD-1390 and AZD-6738, resulting in induced cell apoptosis and inhibited cell growth. DNMT1, ATM, and ATR possess potential as therapeutic targets for AML. Both individual targeting and combination targeting of these molecules have been confirmed as promising therapeutic approaches for AML.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10833198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor neoantigens derived from RNA editing events show significant clinical relevance in melanoma patients treated with immunotherapy. 在接受免疫疗法治疗的黑色素瘤患者中，由 RNA 编辑事件衍生的肿瘤新抗原显示出重要的临床意义。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-12-27 DOI: 10.1097/CAD.0000000000001565

Qicheng Lu, Wenhao Zhou, Ligang Fan, Tian Ding, Wei Wang, Xiaodong Zhang

{"title":"Tumor neoantigens derived from RNA editing events show significant clinical relevance in melanoma patients treated with immunotherapy.","authors":"Qicheng Lu, Wenhao Zhou, Ligang Fan, Tian Ding, Wei Wang, Xiaodong Zhang","doi":"10.1097/CAD.0000000000001565","DOIUrl":"10.1097/CAD.0000000000001565","url":null,"abstract":"This study aimed to investigate the clinical significance of RNA editing (RE) and RNA editing derived (RED-) neoantigens in melanoma patients treated with immunotherapy. Vardict and VEP were used to identify the somatic mutations. RE events were identified by Reditools2 and filtered by the custom pipeline. miRTar2GO was implemented to predict the RE whether located in miRNA targets within the 3' UTR region. NetMHCpan and NetCTLpan were used to identify and characterize RED-neoantigens. In total, 7116 RE events were identified, most of which were A-to-I events. Using our custom pipeline, 631 RED-neoantigens were identified that show a significantly greater peptide-MHC affinity, and facilitate epitope processing and presentation than wild-type peptides. The OS of the patients with high RED-neoantigens burden was significantly longer ( P = 0.035), and a significantly higher RED-neoantigens burden was observed in responders ( P = 0.048). The area under the curve of the RED-neoantigen was 0.831 of OS. Then, we validated the reliability of RED-neoantigens in predicting the prognosis in an independent cohort and found that patients with high RED-neoantigens exhibited a longer OS ( P = 0.008). To our knowledge, this is the first study to systematically assess the clinical relevance of RED-neoantigens in melanoma patients treated with immunotherapy.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139085574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual targeting of Mcl-1 and Bcl-2 to overcome chemoresistance in cervical and colon cancer. Mcl-1和Bcl-2双重靶向治疗癌症颈结肠癌化疗耐药性。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-11-13 DOI: 10.1097/CAD.0000000000001553

Ling Wang, Changlei Xi, Rong Liu, Tingting Ye, Ning Xiang, Jinfang Deng, Hui Li

{"title":"Dual targeting of Mcl-1 and Bcl-2 to overcome chemoresistance in cervical and colon cancer.","authors":"Ling Wang, Changlei Xi, Rong Liu, Tingting Ye, Ning Xiang, Jinfang Deng, Hui Li","doi":"10.1097/CAD.0000000000001553","DOIUrl":"10.1097/CAD.0000000000001553","url":null,"abstract":"After an initial positive response to chemotherapy, cancer patients often become resistant and experience relapse. Our previous research identified eukaryotic translation initiation factor 4E (eIF4E) as a crucial target to overcome chemoresistance. In this study, we delved further into the role and therapeutic potential of myeloid cell leukemia 1 (Mcl-1), an eIF4E-mediated target, in chemoresistance. We showed that the levels of phosphor and total eIF4E, as well as Mcl-1, were elevated in chemoresistant cervical but not colon cancer cells. Mcl-1 inhibitor S64315 decreased Mcl-1 levels in chemoresistant cancer cells, regardless of Mcl-1 upregulation, decreased viability in chemoresistant cancer cells and acted synergistically with chemotherapy drugs. The combined inhibition of Mcl-1 and B-cell lymphoma 2 (Bcl-2), employing both genetic and pharmacological approaches, led to a markedly more substantial decrease in viability compared with the inhibition of either target individually. The combination of S64315 and Bcl-2 inhibitors reduced tumor growth in chemoresistant cervical and colon cancer models without causing general toxicity in mice. This combination also prolonged overall survival compared with using S64315 or venetoclax alone. Our research highlights the therapeutic potential of inhibiting Mcl-1 and Bcl-2 simultaneously in chemoresistant cancers and provides a rationale for initiating clinical trials to investigate the combination of S64315 and venetoclax for the treatment of advanced colon and cervical cancer.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72208170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review. pembrolizumab治疗24个月后的迟发性免疫相关肝炎：病例报告和文献综述。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-11-13 DOI: 10.1097/CAD.0000000000001555

Fernando Salazar González, Cristel Andrea Quiñones Palacios, Alba Manzaneque Gordón, José María Mazarico Gallego, Alba Díaz, Gloria Molas Ferrer

{"title":"Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review.","authors":"Fernando Salazar González, Cristel Andrea Quiñones Palacios, Alba Manzaneque Gordón, José María Mazarico Gallego, Alba Díaz, Gloria Molas Ferrer","doi":"10.1097/CAD.0000000000001555","DOIUrl":"10.1097/CAD.0000000000001555","url":null,"abstract":"Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) pathway have revolutionized cancer immunotherapy by enhancing the immune system's ability to combat cancer cells. However, this innovative approach comes with a distinctive set of challenges, as these therapies can lead to immune-related adverse events (irAEs) due to their mechanism of action. The most common irAEs involve the skin, gastrointestinal tract, liver, endocrine system, and lungs. These events can range from mild skin rashes to severe colitis, pneumonitis, or even autoimmune organ damage. These adverse effects usually appear with an average of 5-15 weeks from the start of treatment depending on the affected organ. This article presents a case report of a delayed related-mediated hepatitis, after 24 months of treatment with pembrolizumab and almost 3 months after its termination, and a review of the scientific literature on cases of delayed immune-related hepatitis caused by anti-PD1. This case highlights the importance of monitoring patients treated with immune checkpoint inhibitors after cessation as a growing number of patients stop treatment due to achieving durable responses.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72208169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy rechallenge of advanced lung adenocarcinoma with cadonilimab (PD-1/CTLA-4 Bi-specific antibody): a case report. 卡多尼单抗(PD-1/CTLA-4双特异性抗体)免疫治疗晚期肺腺癌再挑战1例

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-11-16 DOI: 10.1097/CAD.0000000000001557

Xuan Wang, Kunning Yang, Yang Yang, Xinling Wang, Kede Yuan

引用次数: 0

Acute heart failure following pazopanib treatment: a literature review featuring two case reports. 帕唑帕尼治疗后急性心力衰竭:两例病例报告的文献回顾。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-11-28 DOI: 10.1097/CAD.0000000000001560

Neyran Kertmen, Gozde Kavgaci, Hasan Cagri Yildirim, Omer Dizdar

{"title":"Acute heart failure following pazopanib treatment: a literature review featuring two case reports.","authors":"Neyran Kertmen, Gozde Kavgaci, Hasan Cagri Yildirim, Omer Dizdar","doi":"10.1097/CAD.0000000000001560","DOIUrl":"10.1097/CAD.0000000000001560","url":null,"abstract":"Tyrosine kinase inhibitors (TKIs) have transformed cancer treatment but are associated with cardiovascular toxicity, including heart failure. This review examines the cardiotoxicity of pazopanib, a VEGFR-TKI, through two case reports and explores potential mechanisms. The importance of vigilant clinical monitoring to prevent cardiac dysfunction in cancer patients receiving pazopanib is emphasized. We present two cases of acute heart failure following pazopanib treatment. Case 1 involves a comorbidity-free, 62-year-old woman with metastatic renal cell carcinoma who experienced irreversible heart failure. In case 2, a 40-year-old woman with a history of anthracycline-containing chemotherapy developed reversible left ventricular systolic dysfunction following pazopanib discontinuation. Both patients received appropriate management for their heart failure symptoms. Case 1's condition rapidly deteriorated, leading to her unfortunate demise 3 months after starting pazopanib. In contrast, case 2's cardiac function improved after discontinuing pazopanib. The advent of TKIs has revolutionized cancer treatment, but their association with cardiovascular toxicity necessitates meticulous monitoring of patients. The cases presented here highlight the importance of recognizing and managing cardiotoxicity, particularly in patients without prior cardiovascular risk factors. Understanding the underlying mechanisms and risk factors for TKI-induced heart failure is crucial to optimize patient care and treatment outcomes. Oncologists should be vigilant in identifying clinical symptoms and closely monitoring cardiac function throughout TKI therapy.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138450753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer. 新替利单抗联合阿帕替尼作为三线或三线以上治疗晚期或转移性癌症患者的有效性和安全性。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-11-13 DOI: 10.1097/CAD.0000000000001554

Loulu Gao, Lin Tang, Xiaoqian Li, Jieqiong Peng, Zixuan Hu, Bo Liu

{"title":"Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer.","authors":"Loulu Gao, Lin Tang, Xiaoqian Li, Jieqiong Peng, Zixuan Hu, Bo Liu","doi":"10.1097/CAD.0000000000001554","DOIUrl":"10.1097/CAD.0000000000001554","url":null,"abstract":"This study aimed to evaluate the efficacy and safety of the combination of sintilimab and apatinib for the treatment of patients with advanced or metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer. This retrospective study analyzed data from 34 patients who had advanced or metastatic GC/GEJ cancer and received the combination therapy of sintilimab and apatinib as a third-line or above treatment. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Among the 34 patients, none achieved a complete response (CR), 3 patients (8.8%) achieved a partial response, 23 patients (67.6%) had stable disease, and 8 patients (23.5%) experienced progressive disease. The ORR and DCR were 8.8% and 76.5%, respectively. The median PFS was 6.0 months (95% CI: 3.6-8.4), and the median OS was 11.6 months (95% CI: 8.1-15.1). Subgroup analysis revealed significant differences in OS between patients with high and low Eastern Cooperative Oncology Group Performance Status scores and between patients with and without a history of gastrectomy. Common adverse events (AEs) during treatment included fatigue (52.9%), anemia (47.1%), leukopenia (26.5%), hypothyroidism (23.5%), nausea and vomiting (20.6%), neutropenia (20.6%), and thrombocytopenia (17.6%), most of which were grade 1 and 2 AEs. No deaths occurred due to AEs. These findings indicate that the combination of sintilimab and apatinib has a favorable therapeutic effect in patients with advanced GC. Moreover, the AEs associated with this therapy are generally manageable.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10833188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72208171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2-positive advanced biliary tract cancer responds to second-line pyrotinib therapy: a case report. her2阳性晚期胆道癌对二线吡罗替尼治疗有反应:1例报告。

IF 2.3 4区医学

Anti-Cancer Drugs Pub Date : 2024-03-01 Epub Date: 2023-11-29 DOI: 10.1097/CAD.0000000000001558

Linger Liu, Yao Chen, Xiaolian Zhu, Lisha Zhao, Baisong Chen

{"title":"HER2-positive advanced biliary tract cancer responds to second-line pyrotinib therapy: a case report.","authors":"Linger Liu, Yao Chen, Xiaolian Zhu, Lisha Zhao, Baisong Chen","doi":"10.1097/CAD.0000000000001558","DOIUrl":"10.1097/CAD.0000000000001558","url":null,"abstract":"Biliary tract cancers are solid tumors with poor prognosis and over 70% of patients present in advanced stages. The efficacy of second-line treatment for patients who progressed on GC chemotherapy is limited. Median OS of these patients is less than 1 year with palliative treatment. Despite the success of anti-HER2 therapy in HER2-positive breast cancer, the targeted therapy of HER2 mutations in BTCs is still being explored. This case report is the first report suggesting a 15-month PFS and partial response of pyrotinib in HER2-positive BTC. We report a 64-year-old female with HER2-positive biliary tract cancer. She was diagnosed with AJCC clinical stage IV (cT3N1M1) intrahepatic biliary tract cancer and got PD after 3 cycles of systemic chemotherapy of gemcitabine plus cisplatin. Due to the HER2-positive signature, pyrotinib (400 mg daily in 21-day cycles), an oral irreversible pan-ErbB TKI was prescribed in September 2021, with her informed consent. The tumor shrank significantly after this treatment and imaging assessments conducted on 24 September 2022 showed PR. Until the writing of the case draft, the patient had achieved 15 months of PFS. The present case suggests that Pyrotinib might be a potential effective treatment for HER2-positive advanced BTC.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10833193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138457326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0